Development Technologies Corp.
Limited financial coverage for DVTC.
Not enough data to compute a meaningful composite — typical for foreign-listed ADRs, recent IPOs, or thinly-covered small caps. Live quote, chart, and any available stats still render below.
About the company
Pegasus Pharmaceuticals Inc. develops and supplies the HeartVue 6S System, an advanced electrocardiogram (ECG) device engineered for the non-invasive detection and diagnosis of a spectrum of heart and cardiac conditions. Its utility extends to a broad spectrum of medical practitioners, including cardiologists, general practitioners, and other physicians, and it is utilized across diverse settings such as intensive care units, hospitals, emergency rooms, clinics, fitness centers, sports organizations, and other urgent medical facilities.
- CEO
- Daniel Kesonen
- IPO
- 1997
- HQ
- Palm Beach Gardens, FL, US
Price Chart
- 52W High
- $5.00
- 52W Low
- $5.00
- 50D MA
- $5.00
- 200D MA
- $5.00
- Beta
- 3.24
- Avg Volume
- 2
Get TickerSpark's AI analysis on DVTC
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our DVTC coverage
Recent articles, reports, and earnings notes.
No research on DVTC yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate DVTC report →Similar companies
Peers in the same neighborhood.